Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study

Authors: Shogo Kumagai, Akihiro Ito, Toru Hashimoto, Satoshi Marumo, Hironobu Tokumasu, Aya Kotani, Haruka Yamaki, Masahiro Shirata, Koji Furuuchi, Motonari Fukui, Tadashi Ishida

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Patients with Mycobacterium avium complex (MAC) lung disease (LD) have a heterogeneous prognosis. This study aimed to develop and validate a prognostic scoring model for these patients using independent risk factors for survival.

Methods

We retrospectively analyzed the data of patients with MAC-LD from two hospitals (cohort 1, n = 368; cohort 2, n = 118). Cohort 1 was evaluated using a multivariate Cox proportional hazards model to identify independent risk factors for overall survival (OS). A prognostic scoring model composed of these factors was developed, and cohort 1 was stratified into three groups according to risk using the log-rank test. Finally, the prognostic scoring model was validated using the data of cohort 2.

Results

Seven independent risk factors for OS were selected from cohort 1, including the male sex, age ≥ 70 years, the presence of a malignancy, body mass index <18.5 kg/m2, lymphocyte count <1000 cells/μL, serum albumin levels <3.5 g/dL, and fibrocavitary disease. The areas under the receiver operating characteristic curves for the prognostic scoring model were 0.84 [95% confidence interval (CI), 0.80 − 0.89] for cohort 1 and 0.84 (95% CI, 0.75 − 0.92) for cohort 2. The 5-year OS rates of patients stratified into low-risk, intermediate-risk, and high-risk groups were 97.6, 76.6, and 30.8%, respectively (P < 0.001), in cohort 1, and 97.2, 82.3, and 45.4%, respectively (P < 0.001), in cohort 2.

Conclusions

This study is the first to develop and validate a prognostic scoring model for patients with MAC-LD. This model may prove useful in clinical settings and practical in estimating the prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al., ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al., ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416..
2.
go back to reference Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181:514–21.CrossRefPubMed Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181:514–21.CrossRefPubMed
3.
go back to reference Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970–6.CrossRefPubMedPubMedCentral Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970–6.CrossRefPubMedPubMedCentral
4.
go back to reference Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182:977–82.CrossRefPubMed Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182:977–82.CrossRefPubMed
5.
go back to reference Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium Complex lung disease. Am J Respir Crit Care Med. 2012;185:575–83.CrossRefPubMed Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium Complex lung disease. Am J Respir Crit Care Med. 2012;185:575–83.CrossRefPubMed
6.
go back to reference Okumura M, Iwai K, Ogata H, Yoshiyama T, Yoshimori K, Mizutani S, et al. Clinical studies on the pathogenetic factors of cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium Complex disease. Nihon Kokyuki Gakkai Zasshi. 2006;44:3–12. [in Japanese]PubMed Okumura M, Iwai K, Ogata H, Yoshiyama T, Yoshimori K, Mizutani S, et al. Clinical studies on the pathogenetic factors of cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium Complex disease. Nihon Kokyuki Gakkai Zasshi. 2006;44:3–12. [in Japanese]PubMed
7.
go back to reference Shu CC, Lee CH, Wang JY, Jerng JS, Yu CJ, Hsueh PR, et al., TAMI group. Nontuberculous mycobacteria pulmonary infection in medical intensive care unit: the incidence, patient characteristics, and clinical significance. Intensive. Care. Med. 2008;34:2194–201.. Shu CC, Lee CH, Wang JY, Jerng JS, Yu CJ, Hsueh PR, et al., TAMI group. Nontuberculous mycobacteria pulmonary infection in medical intensive care unit: the incidence, patient characteristics, and clinical significance. Intensive. Care. Med. 2008;34:2194–201..
8.
go back to reference Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
9.
go back to reference Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
10.
go back to reference Field SK, Fisher D, Cowie RL. Mycobacterium avium Complex pulmonary disease in patients without HIV infection. Chest. 2004;126:566–81.CrossRefPubMed Field SK, Fisher D, Cowie RL. Mycobacterium avium Complex pulmonary disease in patients without HIV infection. Chest. 2004;126:566–81.CrossRefPubMed
11.
go back to reference Lande L, Peterson DD, Gogoi R, Daum G, Stampler K, Kwait R, et al. Association between pulmonary Mycobacterium avium Complex infection and lung cancer. J Thorac Oncol. 2012;7:1345–51.CrossRefPubMed Lande L, Peterson DD, Gogoi R, Daum G, Stampler K, Kwait R, et al. Association between pulmonary Mycobacterium avium Complex infection and lung cancer. J Thorac Oncol. 2012;7:1345–51.CrossRefPubMed
12.
go back to reference Fattorini L, Xiao Y, Li B, Santoro C, Ippoliti F, Orefici G. Induction of IL-1 beta, IL-6, TNF-alpha, GM-CSF and G-CSF in human macrophages by smooth transparent and smooth opaque colonial variants of Mycobacterium avium. J Med Microbiol. 1994;40:129–33.CrossRefPubMed Fattorini L, Xiao Y, Li B, Santoro C, Ippoliti F, Orefici G. Induction of IL-1 beta, IL-6, TNF-alpha, GM-CSF and G-CSF in human macrophages by smooth transparent and smooth opaque colonial variants of Mycobacterium avium. J Med Microbiol. 1994;40:129–33.CrossRefPubMed
13.
go back to reference McGarvey J, Bermudez LE. Pathogenesis of nontuberculous mycobacteria infections. Clin Chest Med. 2002;23:569–83.CrossRefPubMed McGarvey J, Bermudez LE. Pathogenesis of nontuberculous mycobacteria infections. Clin Chest Med. 2002;23:569–83.CrossRefPubMed
14.
go back to reference Newman GW, Gan HX, McCarthy PL Jr, Remold HG. Survival of human macrophages infected with Mycobacterium avium intracellulare correlates with increased production of tumor necrosis factor-alpha and IL-6. J Immunol. 1991;147:3942–8.PubMed Newman GW, Gan HX, McCarthy PL Jr, Remold HG. Survival of human macrophages infected with Mycobacterium avium intracellulare correlates with increased production of tumor necrosis factor-alpha and IL-6. J Immunol. 1991;147:3942–8.PubMed
15.
go back to reference Vankayalapati R, Wizel B, Samten B, Griffith DE, Shams H, Galland MR, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium Complex. J Infect Dis. 2001;183:478–84.CrossRefPubMed Vankayalapati R, Wizel B, Samten B, Griffith DE, Shams H, Galland MR, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium Complex. J Infect Dis. 2001;183:478–84.CrossRefPubMed
16.
go back to reference Peek RM Jr, Mohla S, DuBois RN. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res. 2005;65:8583–6.CrossRefPubMed Peek RM Jr, Mohla S, DuBois RN. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res. 2005;65:8583–6.CrossRefPubMed
17.
go back to reference Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.CrossRefPubMed Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.CrossRefPubMed
18.
go back to reference Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;56:167–72.CrossRef Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;56:167–72.CrossRef
19.
go back to reference Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare Complex disease. Int J Tuberc Lung Dis. 2012;16:408–14.CrossRefPubMed Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare Complex disease. Int J Tuberc Lung Dis. 2012;16:408–14.CrossRefPubMed
20.
go back to reference Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759–67.PubMed Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759–67.PubMed
21.
go back to reference Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al., American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212.. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al., American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212..
Metadata
Title
Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study
Authors
Shogo Kumagai
Akihiro Ito
Toru Hashimoto
Satoshi Marumo
Hironobu Tokumasu
Aya Kotani
Haruka Yamaki
Masahiro Shirata
Koji Furuuchi
Motonari Fukui
Tadashi Ishida
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2544-0

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue